Actavis (ACT) Near Deal to Buy Allergan (AGN): Report

According to a Wall Street Journal report that references sources familiar with the matter, Actavis PLC (ACT) and the maker of Botox Allergan, Inc. (AGN) are close to a $62.5 billion merger deal. Under the proposed terms of the transaction, Actavis would pay more than $210 a share, these sources said. By striking a friendly […] View the full post at: Actavis (ACT) Near Deal to Buy Allergan (AGN): Report Related posts: Greece poised to sign rescue deal with EU, IMF CIT Group Cuts Deal with Key Bondholders to Avoid Bankruptcy Goldman’s Role in Lloyd’s Bank Refi Deal Gets Scrutinized